ERYTECH announces enrollment of first patient in Phase I/II study of eryaspase in Acute Lymphoblastic Leukemia in the United States Post author:admERY Post published:July 22, 2014 Post category:Newsroom ERYTECH announces the enrollment of the first patient in its Phase I/II study with eryaspase in Acute Lymphoblastic Leukemia in the United States of America. You Might Also Like ERYTECH Provides Business and Financial Highlights for First Quarter 2016 May 10, 2016 ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update November 12, 2018 ERYTECH to Present Full Results for Phase 2b Trial of eryaspase in Pancreatic Cancer at ESMO 2017 August 31, 2017
ERYTECH to Present Full Results for Phase 2b Trial of eryaspase in Pancreatic Cancer at ESMO 2017 August 31, 2017